| The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements RW Buchanan, J Kreyenbuhl, DL Kelly, JM Noel, DL Boggs, BA Fischer, ... Schizophrenia Bulletin 36 (1), 71-93, 2010 | 1060 | 2010 |
| Schizophrenia Patient Outcomes Research Team (PORT). The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements RW Buchanan, J Kreyenbuhl, DL Kelly, JM Noel, DL Boggs, BA Fischer, ... Schizophr Bull 36 (1), 71-93, 2010 | 279 | 2010 |
| Clinical and preclinical evidence for functional interactions of cannabidiol and Δ9-tetrahydrocannabinol DL Boggs, JD Nguyen, D Morgenson, MA Taffe, M Ranganathan Neuropsychopharmacology 43 (1), 142-154, 2018 | 257 | 2018 |
| The effects of cannabidiol (CBD) on cognition and symptoms in outpatients with chronic schizophrenia a randomized placebo controlled trial DL Boggs, T Surti, A Gupta, S Gupta, M Niciu, B Pittman, ... Psychopharmacology 235, 1923-1932, 2018 | 248 | 2018 |
| Cigarette smoking and mortality risk in people with schizophrenia DL Kelly, RP McMahon, HJ Wehring, F Liu, KM Mackowick, DL Boggs, ... Schizophrenia bulletin 37 (4), 832-838, 2011 | 211 | 2011 |
| Cannabis withdrawal symptoms in non-treatment-seeking adult cannabis smokers KH Levin, ML Copersino, SJ Heishman, F Liu, DL Kelly, DL Boggs, ... Drug and alcohol dependence 111 (1-2), 120-127, 2010 | 188 | 2010 |
| Diagnostic criteria for cannabis withdrawal syndrome DA Gorelick, KH Levin, ML Copersino, SJ Heishman, F Liu, DL Boggs, ... Drug and alcohol dependence 123 (1-3), 141-147, 2012 | 140 | 2012 |
| Effects of the cannabinoid-1 receptor antagonist rimonabant on psychiatric symptoms in overweight people with schizophrenia: a randomized, double-blind, pilot study DL Kelly, DA Gorelick, RR Conley, DL Boggs, J Linthicum, F Liu, ... Journal of clinical psychopharmacology 31 (1), 86-91, 2011 | 75 | 2011 |
| A randomized double-blind trial of atomoxetine for cognitive impairments in 32 people with schizophrenia F Liu, RR Conley The Journal of clinical psychiatry 70 (4), 518-25, 2009 | 54 | 2009 |
| Rimonabant for neurocognition in schizophrenia: a 16-week double blind randomized placebo controlled trial DL Boggs, DL Kelly, RP McMahon, JM Gold, DA Gorelick, J Linthicum, ... Schizophrenia research 134 (2-3), 207-210, 2012 | 51 | 2012 |
| The role of antihistaminic effects in the misuse of quetiapine: a case report and review of the literature BA Fischer, DL Boggs Neuroscience & Biobehavioral Reviews 34 (4), 555-558, 2010 | 45 | 2010 |
| Minimal effects of prolonged smoking abstinence or resumption on cognitive performance challenge the “self-medication” hypothesis in schizophrenia DL Boggs, TS Surti, I Esterlis, B Pittman, K Cosgrove, RA Sewell, ... Schizophrenia research 194, 62-69, 2018 | 40 | 2018 |
| The effects of galantamine on psychopathology in chronic stable schizophrenia RR Conley, DL Boggs, DL Kelly, RP McMahon, D Dickinson, S Feldman, ... Clinical neuropharmacology 32 (2), 69-74, 2009 | 39 | 2009 |
| Going up in smoke? A review of nAChRs-based treatment strategies for improving cognition in schizophrenia D L Boggs, J Carlson, J Cortes-Briones, J H Krystal, D Cyril D'Souza Current pharmaceutical design 20 (31), 5077-5092, 2014 | 38 | 2014 |
| Lack of beneficial galantamine effect for smoking behavior: a double-blind randomized trial in people with schizophrenia DL Kelly, RP McMahon, E Weiner, DL Boggs, D Dickinson, RR Conley, ... Schizophrenia research 103 (1-3), 161-168, 2008 | 37 | 2008 |
| A survey of prescribers' attitudes, knowledge, comfort, and fear of consequences related to an opioid overdose education and naloxone distribution program AM Peckham, ME Niculete, H Steinberg, DL Boggs Journal of public health management and practice 24 (4), 310-317, 2018 | 33 | 2018 |
| Feasibility of reducing the duration of placebo-controlled trials in schizophrenia research RP McMahon, DL Kelly, DL Boggs, L Li, Q Hu, JM Davis, WT Carpenter Jr Schizophrenia bulletin 34 (2), 292-301, 2008 | 33 | 2008 |
| Quetiapine at high doses for the treatment of refractory schizophrenia. DL Boggs, DL Kelly, S Feldman, RP McMahon, MW Nelson, Y Yu, ... Schizophrenia research 101 (1-3), 347-348, 2008 | 33 | 2008 |
| The dose-dependent psychomotor effects of intravenous delta-9-tetrahydrocannabinol (Δ9-THC) in humans DL Boggs, JA Cortes-Briones, T Surti, C Luddy, M Ranganathan, ... Journal of Psychopharmacology 32 (12), 1308-1318, 2018 | 32 | 2018 |
| Cannabis withdrawal in chronic cannabis users with schizophrenia DL Boggs, DL Kelly, F Liu, JA Linthicum, H Turner, JR Schroeder, ... Journal of psychiatric research 47 (2), 240-245, 2013 | 31 | 2013 |
